Related Experiment Video
Updated: Jul 16, 2026

Lipidomics and Transcriptomics in Neurological Diseases
Published on: March 18, 2022
Mutational and expression analysis of CDK1, cyclinA2 and cyclinB1 in epilepsy-associated glioneuronal lesions
V Schick1, M Majores, J Fassunke
1Department of Neuropathology, University of Bonn Medical Centre, Bonn, Germany.
Abstract:
Gangliogliomas and focal cortical dysplasias (FCDs) constitute glioneuronal lesions, which are frequently encountered in biopsy specimens of patients with pharmacoresistant focal epilepsy and relate to impaired differentiation and migration of neural precursors. However, their molecular pathogenesis and relationship are still largely enigmatic. Recent data suggest several components of the insulin-pathway, including TSC1 and TSC2 mutated in tuberous sclerosis complex (TSC), to be altered in gangliogliomas and FCD with Taylor type balloon cells (FCD(IIb)). The proteins tuberin (TSC2) and hamartin (TSC1) constitute a tumour suppressor mechanism involved in cell-cycle control. Hamartin and/or tuberin were reported to colocalize and/or interact with CDK1, cyclinB1 and cyclinA2 that are critically involved in cell-size and cell-growth control. Here, we have carried out mutational and expression analyses of CDK1, cyclinB1 and cyclinA2 in gangliogliomas and FCD(IIb). Mutational screening was performed by single-strand conformation polymorphism analysis in gangliogliomas (n = 20), FCD(IIb) (n = 35) and controls. CyclinB1 revealed a polymorphism (G to A, cDNA Position 966, GenBank: NM_031966) in exon 7 with similar frequencies in FCD(IIb), gangliogliomas and control specimens (FCD n = 9/35; gangliogliomas n = 5/20; control n = 20/100). We used real-time reverse transcription polymerase chain reaction to determine expression levels of CDK1, cyclinB1 and cyclinA2 in 10 FCD(IIb) and nine gangliogliomas compared with unaffected adjacent control tissue of the same patients. We observed significantly lower expression of CDK1 and cyclinA2 in FCD(IIb) vs. controls whereas no significant expression differences were present for CDK1, cyclinB1 and cyclinA2 in gangliogliomas. Our data strongly argue against mutational events of CDK1, cyclinB1 and cyclinA2 to play a role in gangliogliomas or FCD(IIb). However, a potential functional significance of lower expression for the cell-size and cell-cycle regulators CDK1 and cyclinA2 in FCD(IIb) composed of large dysplastic neurones and balloon cells needs to be further resolved.
Insights
This study investigated cell-cycle regulators CDK1, cyclinB1, and cyclinA2 in glioneuronal lesions like gangliogliomas and focal cortical dysplasias (FCDs). Findings suggest mutations are not involved, but reduced CDK1 and cyclinA2 expression may impact FCD(IIb) cell characteristics.
Area of Science:
- Neuroscience
- Molecular Biology
- Oncology
Background:
- Gangliogliomas and focal cortical dysplasias (FCDs) are glioneuronal lesions linked to epilepsy.
- Their molecular pathogenesis and relationship to neural precursor differentiation remain unclear.
- Components of the insulin pathway, such as TSC1 and TSC2, are implicated in these lesions.
Purpose of the Study:
- To investigate the role of cell-cycle regulators CDK1, cyclinB1, and cyclinA2 in gangliogliomas and FCD with Taylor type balloon cells (FCD(IIb)).
- To determine if mutations or altered expression of these regulators contribute to the pathogenesis of these lesions.
Main Methods:
- Mutational analysis using single-strand conformation polymorphism (SSCP) in gangliogliomas (n=20), FCD(IIb) (n=35), and controls.
- Quantitative expression analysis of CDK1, cyclinB1, and cyclinA2 via real-time reverse transcription polymerase chain reaction (RT-PCR) in FCD(IIb) (n=10) and gangliogliomas (n=9) compared to controls.
Main Results:
- No significant mutations in CDK1, cyclinB1, or cyclinA2 were found in gangliogliomas or FCD(IIb).
- A polymorphism in cyclinB1 exon 7 showed similar frequencies across all groups.
- Significantly lower expression of CDK1 and cyclinA2 was observed in FCD(IIb) compared to control tissues, but not in gangliogliomas.
Conclusions:
- Mutational events in CDK1, cyclinB1, and cyclinA2 do not appear to play a role in the pathogenesis of gangliogliomas or FCD(IIb).
- Reduced expression of CDK1 and cyclinA2 in FCD(IIb) may have functional implications for cell-size and cell-cycle regulation in dysplastic neurons and balloon cells.
- Further research is needed to elucidate the functional significance of altered CDK1 and cyclinA2 expression in FCD(IIb).
More Related Videos
08:04Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
Published on: June 6, 2025
08:22A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations
Published on: December 1, 2017